Defensin theta 1, pseudogene (DEFT1P)

Defensin theta 1, pseudogene (DEFT1P) is a human gene locus encoding a non-functional member of the theta-defensin family—cyclic antimicrobial peptides known as retrocyclins in humans and θ-defensins in non-human primates. Unlike other primates, humans carry only a pseudogene due to a premature stop codon that prevents peptide expression[2][5]. Functional θ-defensins are present in some Old World monkeys (e.g., rhesus macaques, baboons), where they are synthesized from precursor proteins, processed, and cyclized into active antimicrobial peptides with antiviral (notably anti-HIV-1) and antibacterial activity[1][2][5][8]. Despite maintenance of an intact coding region, the human DEFT1P gene is not expressed as a protein in vivo under normal physiological conditions[2][5][16]. However, experimental manipulations (e.g., removal of the stop codon or forced ribosomal readthrough) can induce retrocyclin peptide production in human cells, confirming the retained biosynthetic machinery[2][5][11]. Since this locus does not produce a functional protein endogenously, it is not considered a therapeutic target, receptor, enzyme, transporter, or valid biomarker in clinical practice. Clarifications: - The DEFT1P gene is classified as a pseudogene, meaning it is a non-functional gene remnant rather than an active, protein-coding gene or druggable therapeutic target[2][5][16]. - Therapeutic and research interest in this locus centers on synthetic or genetically reactivated retrocyclin/θ-defensin peptides, not the pseudogene itself as an intervention point[5][11]. - Any references to "retrocyclin" or "RTD-1" in the human context concern engineered peptides constructed from the ancestral sequence, not naturally expressed products[2][5][8]. - DEFT1P does not fall into classic molecular target families such as receptor, enzyme, transporter, or ion channel. Information gaps and issues: - is_incorrect: true because DEFT1P is a pseudogene and not a true protein-coding target in humans; any therapeutic relevance relates to synthetic analogs, not the gene itself[2][5][16]. - No clinical drugs or biomarkers act upon or utilize the endogenous DEFT1P gene in humans as a therapeutic or diagnostic target. - No disease roles are assigned to this pseudogene in its native, unmodified state. If structured information is later needed for a functional analog (e.g., synthetic retrocyclin peptide), that would require a separate record under a peptide/biologic name, not as DEFT1P.

Other names

retrocyclintheta-defensin 1 pseudogeneθ-defensin pseudogeneRC1RTD-1 (in macaques, not humans)